3 unchanged sentences
As of February 20, 2025, there were 113,116 holders of record of our common stock.
−Removed: The following summarizes purchases of our common stock during the fourth quarter of 2023 (a) :
+Added: The following summarizes purchases of our common stock during the fourth quarter of 2024:
Period Total Number
−Removed: Purchased (b)
+Added: Purchased (a)
Average Price
4 unchanged sentences
that May Yet Be Purchased
−Removed: Under the Plan (a)
−Removed: October 2 through October 29, 2023
−Removed: 12,222 $ 32.93 — $ 3,292,882,444
+Added: Under the Plan (b)
+Added: September 30 through October 27, 2024 33,110 $ 29.04 — $ 3,292,882,444
October 28 through November 30, 2024 34,233 $ 27.85 — $ 3,292,882,444
−Removed: 25,825 $ 29.95 — $ 3,292,882,444
December 1 through December 31, 2024 63,672 $ 26.21 — $ 3,292,882,444
−Removed: 14,449 $ 28.58 — $ 3,292,882,444
Total 131,015 $ 27.36 —
−Removed: (a) See Note 12 .
−Removed: (b) Represents (i) 49,685 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 2,811 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.
+Added: (a) Represents (i) 127,726 shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of 3,289 shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who deferred receipt of performance share awards.
+Added: (b) See Note 12 .
PEER GROUP PERFORMANCE GRAPH
1 unchanged sentence
and European-based pharmaceutical companies, which are:
−Removed: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi SA, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).
+Added: AbbVie Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eli Lilly and Company, GSK plc, Johnson & Johnson, Merck & Co., Inc., Novartis AG, Novo Nordisk, Roche Holding AG and Sanofi, the S&P 500 Index and the NYSE Arca Pharmaceutical Index (DRG index).
Five Year Performance
6 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.